FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:1573-1576 June 13, 1996 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Drug-resistant tuberculosis has become a major public health problem in the United States.^1,2 In 1979 less than 1 percent of tuberculosis isolates from untreated patients in New York City were resistant to rifampin, as compared with 9 percent in 1991.³ Rifampin-resistant tuberculosis is a serious threat because responses to therapy are more difficult to achieve and require longer courses of treatment.^4,5,6,7,8

Rifabutin is a derivative of rifamycin S that is recommended and widely used as prophylaxis against Mycobacterium avium complex infection in patients infected with the human immunodeficiency virus (HIV) who have low CD4 lymphocyte counts.^9,10 Since rifabutin was introduced . . . [Full Text of this Article]

Case Report

Methods

Results

Discussion

Source Information

From the Departments of Molecular Microbiology and Immunology (W.R.B., C.P.) and Epidemiology (N.M.H.G., R.E.C.), Johns Hopkins University School of Hygiene and Public Health; the Departments of Medicine (W.R.B., R.E.C.) and Pathology (S.H.), Johns Hopkins University School of Medicine; the Baltimore City Health Department (K.M.-R.); and the Maryland Department of Health and Mental Hygiene (N.H.) — all in Baltimore.

Address reprint requests to Dr. Chaisson at Johns Hopkins University School of Medicine, Carnegie 292, 600 N. Wolfe St., Baltimore, MD 21287-6220.

References

This article has been cited by other articles:

• Rastogi, N., Goh, K. S., Berchel, M., Bryskier, A. (2000). Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG. J Antimicrob Chemother 46: 565-570 [Abstract] [Full Text]  
• Subcommittee of the Joint Tuberculosis Committee o, (2000). Management of opportunist mycobacterial infections: Joint Tuberculosis Committee guidelines 1999. Thorax 55: 210-218 [Full Text]  
• SANDMAN, L., SCHLUGER, N. W., DAVIDOW, A. L., BONK, S. (1999). Risk Factors for Rifampin-monoresistant Tuberculosis . A Case-Control Study. Am. J. Respir. Crit. Care Med. 159: 468-472 [Abstract] [Full Text]  
• Bishai, W. R., Graham, N. M. H., Harrington, S., Pope, D. S., Hooper, N., Astemborski, J., Sheely, L., Vlahov, D., Glass, G. E., Chaisson, R. E. (1998). Molecular and Geographic Patterns of Tuberculosis Transmission After 15 Years of Directly Observed Therapy. JAMA 280: 1679-1684 [Abstract] [Full Text]  
• RIDZON, R., WHITNEY, C. G., MCKENNA, M. T., TAYLOR, J. P., ASHKAR, S. H., NITTA, A. T., HARVEY, S. M., VALWAY, S., WOODLEY, C., COOKSEY, R., ONORATO, I. M. (1998). Risk Factors for Rifampin Mono-resistant Tuberculosis. Am. J. Respir. Crit. Care Med. 157: 1881-1884 [Abstract] [Full Text]  
• Goad, J., Jaresko, G. (1997). Tuberculosis in the 90's. Journal of Pharmacy Practice 10: 105-121  
• (1996). Rifampin-Resistant TB Induced by Rifabutin. AIDS Clin Care 1996: 5-5 [Full Text]